Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Somatostatin effects on the proteome of the LNCaP cell-line

Author:
  • Zhaoxu Liu
  • Sofia Bengtsson
  • Morten Krogh
  • M Marquez
  • S Nilsson
  • Peter James
  • A Alaiya
  • Anders Holmberg
Publishing year: 2007
Language: English
Pages: 1173-1179
Publication/Series: International Journal of Oncology
Volume: 30
Issue: 5
Document type: Journal article
Publisher: D.A. Spandidos

Abstract english

Some clinical results indicate that somatostatin (sms) might be useful in the treatment of advanced prostate cancer (HRPC). Because of its transient in vivo half-life only more stable derivatives of sms are of interest in this context. Recent studies have shown that natural sms can be conjugated to a carbohydrate (smsdx) with preservation of sms-like effects on the prostatic tumor cell proteome. The present study identifies some of the affected proteins in an effort to elucidate pathways and proteins that might be of importance for the potential usefulness of sms treatment in HRPC. After incubating the LNCaP cell-line with sms14/smsdx, comparative proteomics was used for analysing and identifying affected proteins. Protein expression patterns were analysed with two-dimensional polyacrylamide gel electrophoresis and mass spectrometry. Catalytic mitochondrial and mitochondrial-associated proteins were significantly affected (fold change approximately 2 or higher) and they were in general up-regulated. Apoptosis-related proteins were both up-regulated (VDAC1, VDAC2) and down-regulated (PRDX2, TCTP). The fold change was >2 for PRDX2 and <2 for the others. There was a strong agreement between sms and smsdx on the up- and down-regulation of proteins. Sms/smsdx triggered up-regulation of catalytic mitochondrial proteins and seemed to affect apoptosis-related proteins. This could indicate important pathways on which smsdx might be able to curb the progression of HRPC. The results encourage a pending clinical phase II study.

Keywords

  • Cancer and Oncology

Other

Published
  • Carl Borrebaeck-lup-obsolete
  • ISSN: 1019-6439
Peter James
E-mail: peter [dot] james [at] immun [dot] lth [dot] se

Professor

Department of Immunotechnology

+46 46 222 14 96

+46 70 247 79 60

MV406411E1

90